Primary Information
According to different authors, at the present time from 4 to 18% of all people suffer from depression throughout his life. The serious impact of depressive disorders is felt both at the individual and the social level. About 4% of the population suffer from panic disorders.
From 1 to 3 October in the all-Russian Exhibition Center of the RUSSIAN Ministry of Health, Moscow research INSTITUTE of psychiatry of Ministry of health of Russia and the Russian society of psychiatrists was Russian conference "Affective and schizoaffective disorder". The main sponsor of the event was a company Lundbek. In the framework of the conference also held meeting of chief psychiatrists, narcologists, and heads of institutions providing psychiatric care. The conference and plenary session was opened with a greeting word the state secretary, deputy Minister of health of the Russian Federation Dedkov DU.
The output from the conference hall the guests were in for a pleasant surprise - the company Lundbek invited the doctors to the friendly lunch with tea, coffee and original cakes. The composition of the tables was supplemented with the symbol of the drug Tsipramil - green apple on a background of red, which is combined with the concept - "... unlike other flawless antidepressant". It is the drug of the group of selective inhibitors of reverse takeover serotonin was devoted to the satellite symposium of company Lundbek on the topic "Modern approaches to the treatment of affective disorders", which took place immediately after the opening of the conference.
The symposium was chaired by Anatoly Smulevich Boleslavovich academician of the Russian ACADEMY of medical sciences, professor, head of the office of the border of mental pathology and psychosomatic disorders, mental health research center of RAMS and His Sergei Nikolaevich md., Professor of the Moscow research INSTITUTE of Psychiatry of ministry of RUSSIAN federation, head of scientific - methodical center of the treatment of mental diseases of the Ministry of health of the RUSSIAN federation.
In the framework of the symposium the following reports were presented:
Sergey Nikolaevich His md., Professor of the Moscow research INSTITUTE of Psychiatry of ministry of RUSSIAN federation, head of scientific - methodical center of the treatment of mental diseases of the Ministry of health of the RUSSIAN federation;
Elena Grigorjevna Kostyukova, md., Professor of the Moscow research INSTITUTE of Psychiatry of ministry of RUSSIAN federation;
Elena Vladimirovna Kolyutskoy, md., Leading researcher of the MHRC (Mental Health Research Center)
Mikhail Yuryevich Drobizheva, professor, md., Leading researcher of the office of the border of mental pathology and psychosomatic disorders, mental health research center of RAMS.
Lundbek (by the name of the founder of the Danish businessman Lundbeck), is the only in the world of international pharmaceutical company, engaged in development, production and sale of drugs for the treatment of only mental and nervous diseases. At present, the company has representative offices in more than 40 countries, and its products can be found all over the world. The Company Lundbek opened its moscow office in September 1997. In the same year in Russia were officially registered three preparation of the company: antidepressant Tsipramil and two neuroleptic - Klopiksol and Flyuanksol. In 2000 there were registered two more of the drug is an antidepressant Saroten and his retardirovannaya form Saroten Retard (amitriptyline) and nejroleptik Truksal (Chlorprothixene). For today the company characterizes the dynamic growth of production of own original psychotropic medications, the expansion of the geography and sales volume increase.
"Selective serotonin reuptake inhibitors: 15 years later".
Report of professor S.N. Mosolov allowed practitioners in the field of psychiatry highlight the benefits applied for over 15 years, the group of selective serotonin reuptake inhibitor (SSRI). Rapporteur highlighted the key stages of confirming the leading role of drugs SSRI in modern therapy with antidepressants. As an example cited the mechanism of the preparation action Tsipramil (Citalopram), which is the most selective inhibitor of serotonin reuptake. In the treatment of a depressive episode and anxiety disorders drug is of the clinical effectiveness has been since the first week of application.
The spectrum of application of antidepressant drug of the group SSRI is not limited to only depressive syndrome. This group is also effective in the treatment of obsessive - compulsive disorders and panic attacks. The author were provides interesting data on the treatment of compulsive shopping, the gambling habit product Citalopram. Rapporteur pay attention to the new antidepressant Tsipraleks production company Lundbek, which is in the process of registration in the Russian Federation and leave the Russian market in the next year. In conclusion of the report of the professor SNMosolov has summed up the results of comparison with tricyclic antidepressants selective inhibitors of reverse takeover serotonin. SSRI according to the report data - more safe in overdose, have low behavioral toxicity, (which determines the possibility of their application in the period of active duty), do not cause the "withdrawal syndrome" in the case of abrupt cessation of therapy, are more suitable for long-term (preventive) therapy, as well as the treatment of the elderly and physically debilitated patients.
"Features of clinical actions tsipramila with depression".
Speech by professor Y.G. Kostyukova concerned antidepressant from the group of selective serotonin reuptake inhibitor (SSRI) - Tsipramila (Citalopram). A considerable advantage of the Tsipramila is it smaller than the other antidepressants potential for drug interactions. This is due to its more low, than in other SSRIS intensity of binding to plasma proteins and inhibition of liver in the system of cytochrome P-450. That is Citalopram not affect the pharmacokinetics of drugs in combined or parallel therapy.
The systemic bioavailability of the drug is 80%. Tsipramil easily (no connection to the reception food) and quickly (in 2 - 4 hours) reaches a maximum concentration in the biological liquids, and his lipotropic provides active substance light penetration through the blood-brain barrier. The average compared with other SSRIS the duration of the period of half-life of the active substance - 30 - 33 hours (against 15 hours for fluvoxamine and 4 to 6 days for fluoxetin administration) guaranteed allows you to take citalopram once a day. Equilibrium concentration in hair oil blend from blood plasma is achieved regardless of the age of the patient rather quickly - by the end of the first week of therapy, that, probably, causes and earlier, than in some other SSRIS the emergence of a therapeutic effect . The rapporteur noted that the simplicity of the treatment of drug - starting dose (20 mg) is both the optimal therapeutic dose, which allows to avoid violations of patients'treatment and, therefore, contributes to the advance of the desired clinical effect.
"Citalopram in the treatment of obsessive - phobic disorders".
The report of the md. EVKolyutskoy touched the hair oil blend from research carried out on the basis of the mental health Research center of RAMS. The sample consisted of 30 patients with panic disorder (18 women and 12 men), the average age of 28 years, duration of the disease 1-20 years (an average of 6.9). The rapporteur noted the effectiveness of the drug in this group. First of all, there was a pronounced anti-panic activity and even a parallel reduction of cognitive and somatic components of the alarm. In addition, it was found that Tsipramil has a favourable tolerability profile, with minimal adverse effects. In addition to applying Tsipramila in patients with panic disorders, proved the effectiveness of the drug in obsessive - compulsive disorders such as ideoobsessivnye disorder (contrasting obsessions, obsessive doubts, learning a presentation, "chatter"), motor disorders (multiple rituals, doubts in the correctness of execution of motion, motor stereotypes).
In the course of studies it is established that the decisive factor determining the strategies of overcoming drug resistance, is the analysis of the structure of comorbidity obsessive-phobic symptom complexes during any with the main manifestations of endogenous process - positive and negative disorders.
"The main properties of the SSRI" ...
To the group of selective serotonin reuptake inhibitor (SSRI), include the preparations not only with different chemical structure, but also significantly different in its pharmacological properties. However, all of them - citalopram, fluoxetine, paroxetine, sertralin, fluvoksamin, share a common property of the inhibition of reverse takeover serotonin.
In his report, professor M.YU. Drobizhev brought possible secondary effects associated with use of antidepressant drug of the group SSRI, which is due to the action in addition to 5NT2 receptors in one degree or another on the blockade of muscarinic, serotonin, adrenergic and GABA-ergic receptors. Secondary effects may be desirable - effectiveness in bulimia, overeating, advantage in the treatment of patients with psychomotor inhibition and undesirable - excessive activation of the patients, strengthening of cognitive disorders, the worst portability in the psycho-motor agitation, anxiety, insomnia, etc . In connection with this often increases the rates of incidence of premature cessation of therapy because of an activating effect.
In the conclusion of the speeches of the rapporteur has concluded that Tsipramil (Citalopram) is the only product, the mechanism of which corresponds exactly to the name of the group SSRI (selective inhibitor of serotonin reuptake), he does not interact with other neurotransmitter systems , and acts selectively in 5NT2 receptors. This leads to the fact, that the side effects of better predictable, their set smaller and the patient is more komplaenten.
Tsipramil (Citalopram)
From the time of its commencement of a clinical study in 1976., Was held, numerous clinical trials and was officially registered in more than 70 countries
From 1 to 3 October in the all-Russian Exhibition Center of the RUSSIAN Ministry of Health, Moscow research INSTITUTE of psychiatry of Ministry of health of Russia and the Russian society of psychiatrists was Russian conference "Affective and schizoaffective disorder". The main sponsor of the event was a company Lundbek. In the framework of the conference also held meeting of chief psychiatrists, narcologists, and heads of institutions providing psychiatric care. The conference and plenary session was opened with a greeting word the state secretary, deputy Minister of health of the Russian Federation Dedkov DU.
The output from the conference hall the guests were in for a pleasant surprise - the company Lundbek invited the doctors to the friendly lunch with tea, coffee and original cakes. The composition of the tables was supplemented with the symbol of the drug Tsipramil - green apple on a background of red, which is combined with the concept - "... unlike other flawless antidepressant". It is the drug of the group of selective inhibitors of reverse takeover serotonin was devoted to the satellite symposium of company Lundbek on the topic "Modern approaches to the treatment of affective disorders", which took place immediately after the opening of the conference.
The symposium was chaired by Anatoly Smulevich Boleslavovich academician of the Russian ACADEMY of medical sciences, professor, head of the office of the border of mental pathology and psychosomatic disorders, mental health research center of RAMS and His Sergei Nikolaevich md., Professor of the Moscow research INSTITUTE of Psychiatry of ministry of RUSSIAN federation, head of scientific - methodical center of the treatment of mental diseases of the Ministry of health of the RUSSIAN federation.
In the framework of the symposium the following reports were presented:
Sergey Nikolaevich His md., Professor of the Moscow research INSTITUTE of Psychiatry of ministry of RUSSIAN federation, head of scientific - methodical center of the treatment of mental diseases of the Ministry of health of the RUSSIAN federation;
Elena Grigorjevna Kostyukova, md., Professor of the Moscow research INSTITUTE of Psychiatry of ministry of RUSSIAN federation;
Elena Vladimirovna Kolyutskoy, md., Leading researcher of the MHRC (Mental Health Research Center)
Mikhail Yuryevich Drobizheva, professor, md., Leading researcher of the office of the border of mental pathology and psychosomatic disorders, mental health research center of RAMS.
Lundbek (by the name of the founder of the Danish businessman Lundbeck), is the only in the world of international pharmaceutical company, engaged in development, production and sale of drugs for the treatment of only mental and nervous diseases. At present, the company has representative offices in more than 40 countries, and its products can be found all over the world. The Company Lundbek opened its moscow office in September 1997. In the same year in Russia were officially registered three preparation of the company: antidepressant Tsipramil and two neuroleptic - Klopiksol and Flyuanksol. In 2000 there were registered two more of the drug is an antidepressant Saroten and his retardirovannaya form Saroten Retard (amitriptyline) and nejroleptik Truksal (Chlorprothixene). For today the company characterizes the dynamic growth of production of own original psychotropic medications, the expansion of the geography and sales volume increase.
"Selective serotonin reuptake inhibitors: 15 years later".
Report of professor S.N. Mosolov allowed practitioners in the field of psychiatry highlight the benefits applied for over 15 years, the group of selective serotonin reuptake inhibitor (SSRI). Rapporteur highlighted the key stages of confirming the leading role of drugs SSRI in modern therapy with antidepressants. As an example cited the mechanism of the preparation action Tsipramil (Citalopram), which is the most selective inhibitor of serotonin reuptake. In the treatment of a depressive episode and anxiety disorders drug is of the clinical effectiveness has been since the first week of application.
The spectrum of application of antidepressant drug of the group SSRI is not limited to only depressive syndrome. This group is also effective in the treatment of obsessive - compulsive disorders and panic attacks. The author were provides interesting data on the treatment of compulsive shopping, the gambling habit product Citalopram. Rapporteur pay attention to the new antidepressant Tsipraleks production company Lundbek, which is in the process of registration in the Russian Federation and leave the Russian market in the next year. In conclusion of the report of the professor SNMosolov has summed up the results of comparison with tricyclic antidepressants selective inhibitors of reverse takeover serotonin. SSRI according to the report data - more safe in overdose, have low behavioral toxicity, (which determines the possibility of their application in the period of active duty), do not cause the "withdrawal syndrome" in the case of abrupt cessation of therapy, are more suitable for long-term (preventive) therapy, as well as the treatment of the elderly and physically debilitated patients.
"Features of clinical actions tsipramila with depression".
Speech by professor Y.G. Kostyukova concerned antidepressant from the group of selective serotonin reuptake inhibitor (SSRI) - Tsipramila (Citalopram). A considerable advantage of the Tsipramila is it smaller than the other antidepressants potential for drug interactions. This is due to its more low, than in other SSRIS intensity of binding to plasma proteins and inhibition of liver in the system of cytochrome P-450. That is Citalopram not affect the pharmacokinetics of drugs in combined or parallel therapy.
The systemic bioavailability of the drug is 80%. Tsipramil easily (no connection to the reception food) and quickly (in 2 - 4 hours) reaches a maximum concentration in the biological liquids, and his lipotropic provides active substance light penetration through the blood-brain barrier. The average compared with other SSRIS the duration of the period of half-life of the active substance - 30 - 33 hours (against 15 hours for fluvoxamine and 4 to 6 days for fluoxetin administration) guaranteed allows you to take citalopram once a day. Equilibrium concentration in hair oil blend from blood plasma is achieved regardless of the age of the patient rather quickly - by the end of the first week of therapy, that, probably, causes and earlier, than in some other SSRIS the emergence of a therapeutic effect . The rapporteur noted that the simplicity of the treatment of drug - starting dose (20 mg) is both the optimal therapeutic dose, which allows to avoid violations of patients'treatment and, therefore, contributes to the advance of the desired clinical effect.
"Citalopram in the treatment of obsessive - phobic disorders".
The report of the md. EVKolyutskoy touched the hair oil blend from research carried out on the basis of the mental health Research center of RAMS. The sample consisted of 30 patients with panic disorder (18 women and 12 men), the average age of 28 years, duration of the disease 1-20 years (an average of 6.9). The rapporteur noted the effectiveness of the drug in this group. First of all, there was a pronounced anti-panic activity and even a parallel reduction of cognitive and somatic components of the alarm. In addition, it was found that Tsipramil has a favourable tolerability profile, with minimal adverse effects. In addition to applying Tsipramila in patients with panic disorders, proved the effectiveness of the drug in obsessive - compulsive disorders such as ideoobsessivnye disorder (contrasting obsessions, obsessive doubts, learning a presentation, "chatter"), motor disorders (multiple rituals, doubts in the correctness of execution of motion, motor stereotypes).
In the course of studies it is established that the decisive factor determining the strategies of overcoming drug resistance, is the analysis of the structure of comorbidity obsessive-phobic symptom complexes during any with the main manifestations of endogenous process - positive and negative disorders.
"The main properties of the SSRI" ...
To the group of selective serotonin reuptake inhibitor (SSRI), include the preparations not only with different chemical structure, but also significantly different in its pharmacological properties. However, all of them - citalopram, fluoxetine, paroxetine, sertralin, fluvoksamin, share a common property of the inhibition of reverse takeover serotonin.
In his report, professor M.YU. Drobizhev brought possible secondary effects associated with use of antidepressant drug of the group SSRI, which is due to the action in addition to 5NT2 receptors in one degree or another on the blockade of muscarinic, serotonin, adrenergic and GABA-ergic receptors. Secondary effects may be desirable - effectiveness in bulimia, overeating, advantage in the treatment of patients with psychomotor inhibition and undesirable - excessive activation of the patients, strengthening of cognitive disorders, the worst portability in the psycho-motor agitation, anxiety, insomnia, etc . In connection with this often increases the rates of incidence of premature cessation of therapy because of an activating effect.
In the conclusion of the speeches of the rapporteur has concluded that Tsipramil (Citalopram) is the only product, the mechanism of which corresponds exactly to the name of the group SSRI (selective inhibitor of serotonin reuptake), he does not interact with other neurotransmitter systems , and acts selectively in 5NT2 receptors. This leads to the fact, that the side effects of better predictable, their set smaller and the patient is more komplaenten.
Tsipramil (Citalopram)
From the time of its commencement of a clinical study in 1976., Was held, numerous clinical trials and was officially registered in more than 70 countries
